Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis

Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis

Background Immune checkpoint inhibitors (ICI) have emerged as a front-line therapy for a variety of solid tumors. With the widespread use of these agents, immune-associated toxicities are increasingly being recognized, including fatal myocarditis. There are limited data on the outcomes and prognosti...

Full description

Saved in:
Bibliographic Details
Main Authors: Edward J Spangenthal, Igor Puzanov, Marc S Ernstoff, Pankit Vachhani, Fumito Ito, Ankita Kapoor, Benjamin Switzer, Poornima Subramanian, Yan V Yatsynovich, David M Jacobs, Maya R Chilbert, Umesh C Sharma, Steven G Feuerstein, Filip Stefanovic, Mark D Hicar, Anne B Curtis, Grace K Dy, Brian J Page, Nikhil Agrawal, Arjun Khunger, Alexander Hattoum, Jerome J Schentag
Format: Article
Language:English
Published: BMJ Publishing Group 2021-06-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/9/6/e002553.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/9/6/e002553.full

Similar Items